NCT04799132 is a clinical trial in Covid19, sponsored by Clínica del country.

Who is sponsoring NCT04799132?

NCT04799132 is sponsored by Clínica del country.

What condition does NCT04799132 study?

NCT04799132 studies Covid19, Obesity, Overweight, Pneumonia, Viral.

Is NCT04799132 still recruiting?

NCT04799132 is currently completed. Last updated 16 March 2021.

Last reviewed 2021-03-16 · How we verify

NCT04799132

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Association Between Body Mass Index and HFNC Therapy Success

Completed Last updated 16 March 2021

What this trial tests

trial in Covid19 in 303 participants. Completed in 1 March 2021.

Timeline

11 March 2020

Primary endpoint
1 March 2021

1 March 2021

Quick facts

Lead sponsor	Clínica del country
Status	Completed
Study type	OBSERVATIONAL
Enrollment	303
Start date	11 March 2020
Primary completion	1 March 2021
Estimated completion	1 March 2021
Sites	1 location across Colombia

Conditions studied

Covid19 — all drugs for Covid19 →
Obesity — all drugs for Obesity →
Overweight — all drugs for Overweight →
Pneumonia, Viral — all drugs for Pneumonia, Viral →

Sponsor

Clínica del country

Who can join

18 and older, any sex, with Covid19 or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients over 18 years of age who are admitted to the Intermediate Care Unit of the Clinica del Country and the Clinica la Colina, with symptoms suggestive of severe pneumonia secondary to COVID-19 infection and acute hypoxemic respiratory failure. The primary outcome will be to determine the relationship between body mass index and high-flow cannula therapy success defined as: No need for mechanical ventilation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04799132 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Clínica del country
Last refreshed: 16 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04799132.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing